Larry represents leading global companies in complex business disputes and class actions, often with a cross-border component, in federal and state courts.

Larry advises clients on complex business litigation, including securities and corporate governance litigation, commercial disputes, and related regulatory investigations. He specializes in representing financial institutions, large public companies, boards, and senior executives in:

  • Securities class actions
  • M&A disputes
  • Shareholder derivative litigation
  • Other complex, high-exposure litigation

Larry was previously a judicial intern at the United States District Court for the Southern District of New York and an associate at Latham’s London office.

Larry’s recent experience includes advising:

  • Vroom, Inc. in a securities class action following IPO, resulting in full dismissal (S.D.N.Y. 2025)
  • A global investment advisor in litigation related to CLOs, resulting in dismissal and affirmed on appeal (S.D.N.Y 2024 and 2d Cir. 2025)
  • President and CEO of a global animal health company in a take-private stockholder class action, resulting in full dismissal with prejudice (Del. Ch. 2024) (Transcript)
  • The underwriters of MINISO’s IPO in a securities class action, resulting in complete dismissal (S.D.N.Y. 2024)
  • Sinovac Biotech Ltd. in:
    • Shareholder litigation concerning its 2018 PIPE transaction, resulting in dismissal with prejudice (D. Mass. 2023)
    • Shareholder litigation relating to the implementation of its poison pill, resulting in complete dismissal (Del. Ch. 2024)
  • A leading pool equipment manufacturer in a securities class action concerning channel stuffing allegations, resulting in full dismissal (D.N.J. 2024)
  • A Chinese internet security company in a securities class action concerning its take-private transaction, resulting in dismissal of over 99% of claimed damages (S.D.N.Y. 2023)
  • An exercise equipment company in defeating class certification and achieving a partial dismissal of claims in consumer class action alleging false advertising (S.D.N.Y. 2023)
  • Mallinckrodt Pharmaceuticals in reorganizing under chapter 11, following numerous contested matters and hotly contested confirmation hearing (Bankr. D. Del. 2022)

Bar Qualification

  • New York

Education

  • JD, Duke University School of Law, 2020
  • MA in Economic Law, Sciences Po Paris, 2020
  • BA in Political Science & Philosophy, Columbia University, 2017

Languages Spoken

  • English
  • Chinese (Mandarin)
  • French